These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21192140)

  • 1. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.
    Daly EJ; Trivedi MH; Fava M; Shelton R; Wisniewski SR; Morris DW; Stegman D; Preskorn SH; Rush AJ
    J Clin Psychopharmacol; 2011 Feb; 31(1):31-8. PubMed ID: 21192140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
    Warden D; Trivedi MH; Wisniewski SR; Kurian B; Zisook S; Kornstein SG; Friedman ES; Miyahara S; Leuchter AF; Fava M; Rush AJ
    J Clin Psychopharmacol; 2010 Jun; 30(3):259-66. PubMed ID: 20473060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
    Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW
    Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT; Hassman HA; Glass SJ; McManus FC
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
    Zisook S; Trivedi MH; Warden D; Lebowitz B; Thase ME; Stewart JW; Moutier C; Fava M; Wisniewski SR; Luther J; Rush AJ
    J Affect Disord; 2009 Sep; 117(1-2):63-73. PubMed ID: 19217668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
    Rucci P; Frank E; Scocco P; Calugi S; Miniati M; Fagiolini A; Cassano GB
    Depress Anxiety; 2011 Apr; 28(4):303-9. PubMed ID: 21308882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Hong J; Novick D; Montgomery W; Moneta MV; Dueñas H; Peng X; Haro JM
    Asia Pac Psychiatry; 2016 Mar; 8(1):51-9. PubMed ID: 25808275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.